

and adenocarcinoma in situ. This reduction in cytological abnormalities, treatment of CIN and its associated follow-up is likely to have the greatest impact in the UK and other developed countries in terms of health care costs and the social and emotional costs to women. After 1–3 decades the vaccinated cohort should show a reduction of 70% in the incidence of cervix cancer and if screening has continued and if its coverage has been maintained at current levels then the reduction could reach more than 90%. If HPV 6 and 11 are included in the vaccine mix then in a reasonably short time period genital wart incidence would be reduced by more than 90%. This really does look like the beginning of the end for HPV-associated disease in women.

Statements on funding and competing interests

Funding None identified.

Competing interests The author is a consultant for Merck Vaccines, GlaxoSmithKline Biologicals and Sanofi Pasteur MSD.

References

- 1 Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. *Vaccine* 2006; **24**(Suppl. 3): S11–S25.
- 2 Garland SM, Hernandez-Avila M, Wheeler CM, *et al.* Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. *N Engl J Med*. 2007; **356**: 1928–1943.
- 3 Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. *Lancet* 2007; **369**: 1861–1868.
- 4 Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, *et al.*; HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. *Lancet* 2007; **369**: 2161–2170.
- 5 Centres for Disease Control and Prevention (CDC). <http://www.cdc.gov/nip/ACIP/slides/feb07/08-hpv-2-barr.pdf> [Accessed 5 August 2007].
- 6 Fraser C, Tomassini JE, Xi L, Golm G, Watson M, Giuliano AR, *et al.* Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. *Vaccine* 2007; **25**: 4324–4333.
- 7 Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, *et al.* Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. *Vaccine* 2007; **25**: 4931–4939.
- 8 Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, *et al.* Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. *Vaccine* 2006; **24**: 5937–5949.
- 9 Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, *et al.*; Protocol 016 Study Group. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. *Pediatrics* 2006; **118**: 2135–2145.
- 10 Bosch FX, de Sanjosé S. Chapter 1: Human papillomavirus and cervical cancer – burden and assessment of causality. *J Natl Cancer Inst Monogr* 2003; **31**: 3–13.
- 11 Sasieni P, Adams J, Cuzick J. Benefits of cervical screening at different ages: evidence from the UK audit of screening histories. *Br J Cancer* 2003; **89**: 88–93.
- 12 Kitchener HC, Castle PE, Cox JT. Chapter 7: Achievements and limitations of cervical cytology screening. *Vaccine* 2006; **24**(Suppl. 3): S63–S70.
- 13 Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. *Vaccine* 2006; **24**(Suppl. 3): S26–S34.

FACULTY MEMBERSHIP EXAMINATION

The Membership Examination (MFFP) consists of:

☐ Part 1 Multiple Choice Question Paper (MCQ)

This 1½-hour paper consists of 50 clinical science and applied science questions.

The examination will be held in London on **Wednesday 23 April 2008** and **Friday 17 October 2008**. Applications for April 2008 must be received by **1 January 2008** and those for October 2008 must be received by **1 July 2008**. The application form and information on the Part 1 can be obtained from the Faculty of Family Planning website (www.ffprhc.org.uk).

☐ Dissertation or Case Reports

Submission of one Dissertation (10 000 words) or two Case Reports (3000 words each).

Please visit the Faculty of Family Planning website (www.ffprhc.org.uk) for the latest changes to this part of the examination, and for information on exemptions.

☐ Part 2 Examination (CRQ, MEQ, OSCE)

This all day examination consists of:

Critical Reading Question examination paper (CRQ)

Modified Essay Question examination paper (MEQ)

Objective Structured Clinical Examination (OSCE)

Applications for the **MFFP Part 2** held in **June 2008** must be received by **3 January 2008**. Information on the Part 2 examination, the Examination Regulations and the application form appear on the Faculty of Family Planning website (www.ffprhc.org.uk).

The qualification is subject to re-certification every 5 years.

For the MFFP Examination Regulations (December 2005), information and application forms please visit the Faculty of Family Planning website: www.ffprhc.org.uk (see **Training & Exams** and **MFFP Member**). Also available on request from: Mrs Denise Pickford, Examinations, Faculty of Family Planning and Reproductive Health Care of the Royal College of Obstetricians and Gynaecologists, 27 Sussex Place, Regent's Park, London NW1 4RG, UK. Tel: +44 (0) 20 7724 5629. Fax: +44 (0) 20 7723 5333. E-mail: denise@ffprhc.org.uk